Shire said on Monday it was ready to recommend a newly revised higher offer from AbbVie, valuing the London-listed drugmaker at £53.20 pounds ($90.53) per share.

AbbVie, which wants to buy Shire to cut its tax bill and diversify its product line-up, raised its cash-and-stock offer for Shire to £51.15 a share last Tuesday.